Manmeet Singh Ahluwalia, MD, MBA, FASCO

Area:

Website:

Google:

Bio:

Manmeet Ahluwalia, MD, MBA, FASCO is the Chief Scientific Officer and the Deputy Director of the Miami Cancer Institute (MCI) at Baptist Health South Florida in Miami, FL, United States (https://miami-cancer-doctors.baptisthealth.net/provider/Manmeet+Singh+Ahluwalia/1832154). MCI was the third full member of Memorial Sloan Kettering’s (MSK) Cancer Alliance. MCI is currently the only MSK Cancer Alliance member and the fifth-largest cancer center in the state of Florida. He is also a full professor of translational medicine in Herbert Wertheim College of Medicine at Florida International University.

Prior to his current physician-executive role, Prof Ahluwalia was a full professor and physician-scientist at the prestigious Cleveland Clinic, where built the Burkhardt Brain Tumor and Neuro-Oncology Center into a world leader in brain tumors trials as the head of operations and the Miller Family Endowed Chair in Neuro-Oncology. His greatest accomplishment has been his research-capacity building at the level of institutions, centers, and individuals, and he has been recognized as part of the American Society of Clinical Oncology (ASCO) Leadership Development Program. He has been the recipient of FASCO, considered the highest award by ASCO as well.

Dr. Ahluwalia is a US National Institutes of Health (NIH) >3 million USD R01 grant-funded investigator. He has conceptualized and led landmark clinical trials across the US that have changed clinical practice in brain tumors. He also serves as a clinical trial leader on a landmark NIH (PO1) >10 million USD grant that aims to determine gender-specific differences in brain tumors. He has been and continues to be the principal investigator on several ongoing paradigm-changing FDA-approval-intent studies. Additionally, he serves on the editorial boards of major journals publishing brain tumor research. His research has been published across 200+ peer-reviewed papers, including JAMA, JAMA Oncology, Neuro-Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, and Nature Reviews Clinical Oncology, amongst others.

He recently was the lead author of the landmark paper describing the novel use of a vaccine called SurVaxM for glioblastoma (the most aggressive brain tumor) in the Journal of Clinical Oncology, the world’s most prestigious journal for oncology. This has received extensive media coverage, including by OncLive, considered the voice of the Global Oncology community (https://www.onclive.com/view/dr-ahluwalia-on-the-evaluation-of-survaxm-with-temozolomide-in-newly-diagnosed-glioblastoma).

Currently, as MCI’s chair of medical oncology and as the Fernandez Family Endowed Chair in Cancer Research, he supervises 25+ oncologists, while as the Chief Scientific Officer, he supports the research of 120+ physicians, He also chairs the Scientific Advisory Council of the Guardian Research Network (GRN), a non-profit community hospital research consortium (https://www.prnewswire.com/news-releases/guardian-research-network-forms-scientific-advisory-council-to-ensure-real-world-data-continues-to-positively-impact-clinical-research-301580027.html). He is widely considered a thought leader in the neuro-oncology community across North America.
(Show less)

Mean distance: (not calculated yet)